References
- Giuliani F. C., Spreafico F., Casazza A. Pre-clinical studies on new anthracyclines: antitumor toxicologic and pharmacologic properties. An-thrcyclines and Cancer Therapy, H. H. Hansen. Ex-cerpta Medica, Amsterdam 1983; 193–207
- Investigational Drug Brochure: 4-Demethoxydaunonibicin. Farmitalia Carlo Erba, MilanItaly
- Caszaa A. M. Experimental evaluation of anthra-cycline analogs. Cancer Treat. Rep. 1979; 63: 835–839
- Casazza A. M., Bertazzoli C., Pratesi G., Bellini O., Di Marco A. Antileukemic activity and cardiac tox-icity of 4-demethoxydaunorubicin (4-DMDR) in mice. Proc. Am. Asoc. Cancer Res., (Abstracts) 1979; 20: 16
- Bonfante V., Ferrari L., Villani F., Bonadoona G. Phase I study of 4-demethoxydaunorubicin. Invest. New Drugs 1983; I: 161–168
- Kaplan S., Sessa C., Willems Y., Pacciarini M. A., Ta-massia V., Cavalli F. Phase I trial of 4-demethoxydaunorubicin (Idarubicin) with single oral doses. Invest. New Drugs 1984; 2: 281–286
- Coonley C. J., Warrel R. P., Jr., Straus D. J., Young C. W. Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma. Cancer Treat. Rep. 1983; 67: 949–950
- Eridani S., Slater N. G.P., Singh A. K., Pearson T. C. Intravenous and oral demethoxydaunorubicin (NSC256–439) in the treatment of acute leukemia and lymphoma: a pilot study. Blut 1985; 50: 369–372
- Ganzina F., Pacciarini M. A., DiPietro N. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. Invest. New Drugs 1986; 4: 85–105
- Lopez M., DiLauro L., Papaldo P. Oral ida-rubicin in non-Hodgkin's lymphomas. Invest. New Drugs 1986; 4: 263–267
- Gillies H., Liang R., Rogers H., Harper P., Parapia L., Cox G., Johnson S. Phase II trial of idarubicin in patients with advanced lymphomas. Cancer Chemother. Pharmacol. 1988; 21: 261–264
- Case D. C., Jr., Hayes D. M., Gerber M., Gams R., Ervin T. J., Dorsk B. M. Phase II study of oral idarubicinin favourable histology non-Hodgkin's lymphoma. Cancer Res. 1990; 50: 6833–6835
- Errante D., Sorio R., Zagonel V., Carbone A., Mon-fardini S., Tirelli U. A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma. Am. J. Clin. Oncol. 1991; 14(3)243–245
- Armitage J. C., Dick F. R., Corder M. P., et al. Predicting therapeutic outcome in patients with difuse his-tiocytic lymphoma treated with cyclophosphamide, adria-mycin, vincristine, and prednisone (CHOP). Cancer 1982; 50: 1695–1702
- Gerard-Marchant R., Hamlin I., Lennert K., et al. Classification of non-Hodgkin lymphoma. Lancet 1974; II: 406–410
- Carbone P. P., Kaplan H. S., Musshoff K., et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860–1861
- Hoff J., Horowitz M. Clinical echocardiography. Futura, New York, NY 1978
- WHO handbook of reporting results of cancer treatment. WHO offset publication No. 48. WHO, GenevaSwitzerland 1979